Intrommune CEO, Michael Nelson, spoke with PetaCrunch about Intrommune’s approach to treating peanut allergies In the News / By Intrommune
Intrommune selected as Semifinalist in the Innovate Children’s Health Challenge In the News / By Intrommune
Senior Medical Advisor, William Reisacher, interviewed on the Price of Business with Kevin Price In the News / By Intrommune
Proactive Interview: Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process In the News / By Intrommune
Providing Innovative Treatments for Peanut Allergies Intrommune CEO, Michael Nelson, interview on the Price of Business with Kevin Price In the News / By Intrommune
Science News: Liquid mouth drops could one day protect people from peanut allergies In the News / By Intrommune
Intrommune Therapeutics selected as one of the RESI NYC Innovation Challenge Finalists In the News / By Intrommune
Intrommune Senior Scientific Advisor, Dr. Reisacher, featured in SELF article: Southwest Airlines Is Finally Getting Rid of In-Flight Peanuts In the News / By Intrommune
Q&A with Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics developing a revolutionary new Drug Delivery method using Toothpaste to Deliver an Oral Mucosal Immunotherapy for People who have a Peanut Allergy In the News / By Intrommune
